Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Pulmatrix Inc
PULM | US
1.32
USD-0.07
-5.04%
PULM | US
About Pulmatrix Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
1.32
Open
1.34
High
1.38
Low
1.27
Pulmatrix Inc. a clinical stage biotechnology company discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800 a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for patients with stable moderate-severe chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100 an iSPERSE formulation of dihydroergotamine for the treatment of acute migraine. The company has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates; and a development and commercialization agreement with Cipla Technologies LLC for the development and commercialization of PUR1900. Pulmatrix Inc. was founded in 2003 and is headquartered in Lexington Massachusetts.
View LessPULM | US
Risk
43.8
Sharpe
-1.05
Luna's Score
37/100
Recommendation
Sell
Luna says (PULM | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
51.6%1 month
43.8%3 months
90.1%6 months
108.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.56
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
1.57
Ent. to rev.
0.00
PEG
-
Other Fundamentals
EBITDA
-11.14M
MarketCap
4.82M
MarketCap(USD)
4.82M
Div. yield
-
Op. margin
-380.22
Erngs. growth
-
Rev. growth
-15.80
Ret. on equity
-58.99
Short ratio
0.48
Short perc.
0.14
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.21
Range1M
0.23
Range3M
1.33
Volumes: Market Activity
Rel. volume
1.60
Price X volume
38.98K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.57 | - | Expensive |
| Ent. to Revenue | 0.00 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.56 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 90.07 | - | Riskier |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 4.82M | - | Emerging |
